On Dec. 12, Biogen said two of its drugs that treat multiple sclerosis, Avonex and Plegridy, will not be discounted through 340B entities’ partner pharmacies. 340B Health President and CEO Maureen Testoni said the decision, which Biogen said will take place Feb. 1, is “depriving safety-net hospitals of needed resources from mandated 340B discounts and keeping those dollars.”
The other pharmaceutical companies that have made similar moves are AbbVie, Amgen, AstraZeneca, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Exelixis, Gilead, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, UCB and United Therapeutics, according to 340B Health.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
